Rubius Therapeutics, Inc. — Form D
Rubius Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2017-06-22. The offering totals $120.0M, of which $115.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2017-06-22
- Form: D
- Accession: 0001709401-17-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $120.0M
- Amount sold: $115.0M
- Remaining: $5.0M
- Investors: 16
- Date of first sale: 2017-06-07
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-289273
Issuer
- Name: Rubius Therapeutics, Inc.
- CIK: 0001709401
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2013
- Address: 325 VASSAR STREET, SUITE 1A, CAMBRIDGE, MA, 02139
- Phone: 617-679-9600
Officers, directors & promoters (15)
| Name | Role | Location |
|---|
| Peter Barton Hutt | Director | Salt Lake City, UT |
| Harvey F Lodish | Director | Cambridge, MA |
| Michael Barton Rosenblatt | Director | Cambridge, MA |
| Robert S Langer | Director | Newton, MA |
| Christopher L Carpenter | Executive Officer | Cambridge, MA |
| Torben Straight Nissen | Director | Cambridge, MA |
| Torben Straight Nissen | Executive Officer | Cambridge, MA |
| Francis B Cuss | Director | Cambridge, MA |
| Catherine B Sohn | Director | Cambridge, MA |
| Michael S Rosenblatt | Director | Cambridge, MA |
| Roger S Pomerantz | Director | Cambridge, MA |
| Joanne Protano | Executive Officer | Cambridge, MA |
| David Straight Epstein | Director | Cambridge, MA |
| Andrew B Oh | Executive Officer | Cambridge, MA |
| Noubar B Afeyan | Director | Cambridge, MA |
Other filings by this issuer (1)
More